Suchergebnisse - "De Jong, Dirk"

PubPharm (14)

1

Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients : Two-year Follow-up of a Prospective Observational Cohort Study

enthalten in: Inflammatory bowel diseases | 2019

von Smits, L. | van Esch, A. | Derikx, L. | +4

2

Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease

enthalten in: Digestive diseases and sciences | 2017

von Smits, L. | Grelack, A. | Derikx, L. | +5

CommentIn: Dig Dis Sci. 2017 Nov;62(11):2964-2965. - PMID 28776140

3

Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients : A Prospective Observational Cohort Study

enthalten in: Journal of Crohn's & colitis | 2016

von Smits, L. | Derikx, L. | de Jong, D. | +4

CommentIn: Nat Rev Gastroenterol Hepatol. 2016 Jun;13(6):314. - PMID 27165513

4

Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNFα Therapy

enthalten in: Journal of Crohn's & colitis | 2015

von van der Valk, M. | Mangen, M. | Severs, M. | +21

5

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy : results from the COIN study

enthalten in: Gut | 2014

von van der Valk, M. | Mangen, M. | Leenders, M. | +19

CommentIn: Gastroenterology. 2014 Jan;146(1):309-11. - PMID 24269567

6

Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2013

von Kestens, C. | van Oijen, M. | Mulder, C. | +9

7

Elective switching from infliximab to adalimumab in stable Crohn's disease

enthalten in: Inflammatory bowel diseases | 2013

von Hoentjen, F. | Haarhuis, B. | Drenth, J. | +1

8

Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro

enthalten in: Digestive diseases and sciences | 2012

von de Vries, H. | de Heij, T. | Roelofs, H. | +3

9

Appropriate infliximab infusion dosage and monitoring : results of a panel meeting of rheumatologists, dermatologists and gastroenterologists

enthalten in: British journal of clinical pharmacology | 2011

von de Vries, H. | van Oijen, M. | Driessen, R. | +4

10

Safety of infliximab in inflammatory bowel disease needs to be debated

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2009

von de Vries, H. | Van Oijen, M. | de Jong, D.

CommentOn: Clin Gastroenterol Hepatol. 2008 Nov;6(11):1212-7; quiz 1176. - PMID 18848503